[Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].
Katagiri
Satoshi
S
Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University.
Tokushige
Katsutoshi
K
Yamamoto
Masakazu
M
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D005260:Female; D006498:Hepatectomy; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a